4,4-dimethylcholesta-8,14-dien-3-ol: RN refers to (3beta,5alpha)-isomer; a meiosis-activating sterol
4,4-dimethyl-8,14-cholestadien-3beta-ol : A cholestanoid that is 5alpha-cholesta-8,14-dien-3beta-ol bearing two additional methyl substituents at position 4.
ID Source | ID |
---|---|
PubMed CID | 167817 |
CHEBI ID | 78904 |
SCHEMBL ID | 6407395 |
MeSH ID | M0194974 |
Synonym |
---|
cholesta-8,14-dien-3-ol, 4,4-dimethyl-, (3beta,5alpha)- |
19456-83-8 |
(3s,5r,10s,13r,17r)-4,4,10,13-tetramethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,5,6,7,11,12,16,17-decahydrocyclopenta[a]phenanthren-3-ol |
4,4-dimethyl-5alpha-cholesta-8,14-dien-3beta-ol |
LMST01010277 |
4,4-dimethyl-5alpha-cholesta-8,14-diene-3beta-ol |
4,4-dcdo |
4,4-dimethylcholesta-8,14-dien-3-ol |
CHEBI:78904 |
(3beta,5alpha)-4,4-dimethylcholesta-8,14-dien-3-ol |
4,4-dimethyl-8,14-cholestadien-3beta-ol |
SCHEMBL6407395 |
cholesta-8,14-dien-3-ol, 4,4-dimethyl-, (3.beta.,5.alpha.)- |
5.alpha.-cholesta-8,14-dien-3.beta.-ol, 4,4-dimethyl-,acetate |
5.alpha.-cholesta-8,14-dien-3.beta.-ol, 4,4-dimethyl- |
cholesta-8,14-dien-3-ol, 4,4-dimethyl-, (3.beta.,5.alpha.)-acetate |
4,4-dimethylcholesta-8,14-dien-3-ol # |
OGQJUYXFIOFTMA-PBJLWWPKSA-N |
4,4-dimethyl-5a-cholesta-8,14-dien-3b-ol |
(3b,5a)-4,4-dimethylcholesta-8,14-dien-3-ol |
4,4-dimethyl-5 alpha-cholesta-8,14-diene-3 beta-ol |
4,4-dimethylcholesta-8,14-dien-3-ol, (3beta)-isomer |
t-mas |
4,4-dimethyl-5a-cholesta-8,14-diene-3b-ol |
Q27148018 |
DTXSID40941201 |
Excerpt | Relevance | Reference |
---|---|---|
" The ovarian 4,4-dimethylsterol response was followed with regard to time and dose-response to the gonadotropins and the resumption of meiosis was evaluated using histologic sections." | ( Gonadotropin-induced accumulation of 4,4-dimethylsterols in mouse ovaries and its temporal relation to meiosis. Baltsen, M, 2001) | 0.31 |
Class | Description |
---|---|
3beta-sterol | A sterol in which the hydroxy group at position 3 has beta- configuration. |
cholestanoid | Any steroid based on a cholestane skeleton and its derivatives. |
tetracyclic triterpenoid | Any triterpenoid consisting of a tetracyclic skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 9 (90.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.42) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |